Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients

Table 1 Immediate AEs by injection session (n = 15,565)

	Incidence¹per injection session			Regression of AEs²
Bleeding	529	(3.4%)	[3.1%; 3.7%]	425/455 (93.4%)
Bruising	365	(2.3%)	[2.1%; 2.6%]	299/324 (92.3%)
Pain	319	(2.0%)	[1.8%; 2.3%]	264/285 (92.6%)
Redness at point of injection	257	(1.6%)	[1.4%; 1.9%]	212/236 (89.8%)
Facial oedema	107	(0.7%)	[0.6%; 0.8%]	97/101 (96.0%)

ISSN: 1471-2334